2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Sunday, October 21, 2018

4:30PM-6:00PM: Abstract Number: 925

Abortive Viral Infection Becomes Macrophage Activation Syndrome in Mice with Chronically Elevated Interleukin-18: Evidence for Synergy with Cytotoxic Impairment

3S106 ACR Abstract: Pediatric Rheumatology–Basic Science (922–927)

4:30PM-6:00PM: Abstract Number: 975

Alteration of Vascular Inflammatory Markers in SLE By Anifrolumab in the Phase IIb Muse Study

3S110 ACR Abstract: SLE–Clinical I: Clinical Trials (970–975)

4:30PM-6:00PM: Abstract Number: 972

An Anti-CD28 Domain Antibody, Lulizumab, in Systemic Lupus Erythematosus: Results of a Phase II Study

3S110 ACR Abstract: SLE–Clinical I: Clinical Trials (970–975)

4:30PM-6:00PM: Abstract Number: 922

Anakinra Treatment Prevents Myocardial Mechanical Dysfunction and Inhibits Histologic Evidence of Myocardial Inflammation in the Mouse Model of Kawasaki Disease

3S106 ACR Abstract: Pediatric Rheumatology–Basic Science (922–927)

4:30PM-6:00PM: Abstract Number: 970

Baricitinib in Patients with Systemic Lupus Erythematosus: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study

3S110 ACR Abstract: SLE–Clinical I: Clinical Trials (970–975)

4:30PM-6:00PM: Abstract Number: 957

Biomechanical Therapy for Osteoarthritis of the Knee: A Randomized Controlled Trial

3S105 ACR Abstract: Osteoarthritis–Clinical (952–957)

4:30PM-6:00PM: Abstract Number: 956

Bone Mineral Density Is a Causal Risk Factor for Knee and Hip Osteoarthritis: A Population-Based and Mendelian Randomization Study in the UK Biobank

3S105 ACR Abstract: Osteoarthritis–Clinical (952–957)

4:30PM-6:00PM: Abstract Number: 941

Causal Inference Methods for the Effect of Rheumatoid Arthritis on Mortality Independent of Lifestyle and Clinical Factors before and after RA Diagnosis

3S102 ACR Abstract: Epidemiology & Pub Health I: Morbidity & Mortality (940–945)

4:30PM-6:00PM: Abstract Number: 966

Central Triage Clinic for Psoriatic Arthritis – Performance of Triage Methods

3S111 ACR Abstract: Spondyloarthritis Incl PsA–Clinical II: PsA Epidemiology (964–969)

4:30PM-6:00PM: Abstract Number: 947

Clinical Characteristics and Outcome after Treatment of a National Cohort of PCR-Positive Lyme Arthritis

3S104 ACR Abstract: Infection-Related Rheumatic Disease (946–951)

4:30PM-6:00PM: Abstract Number: 965

Defining Cutoffs Corresponding to Low Levels of Disease Activity in Psoriatic Arthritis, Using the Patient-Reported Psoriatic Arthritis Impact of Disease Questionnaire (PsAID12). an Analysis of 436 Patients

3S111 ACR Abstract: Spondyloarthritis Incl PsA–Clinical II: PsA Epidemiology (964–969)

4:30PM-6:00PM: Abstract Number: 938

Dermal Lymphatic Dysfunction and Photosensitivity in the MRL/Lpr Lupus Model

3S109 ACR Abstract: SLE–Animal Models (934–939)

4:30PM-6:00PM: Abstract Number: 948

Effects of Antiretroviral Therapy with Tenofovir and Other Antiretroviral Drugs on the Inflammatory State and Bone Remodeling on Newly Diagnosed HIV-Patients at Basal and 3 Months after Starting Treatment

3S104 ACR Abstract: Infection-Related Rheumatic Disease (946–951)

4:30PM-6:00PM: Abstract Number: 952

Effusion-Synovitis and Infrapatellar Fat Pad Edema Differentiate Accelerated Knee Osteoarthritis: Data from the Osteoarthritis Initiative

3S105 ACR Abstract: Osteoarthritis–Clinical (952–957)

4:30PM-6:00PM: Abstract Number: 953

Evaluating MRI-Detected Knee Inflammation Prior to Total Knee Replacement As a Predictive Biomarker of Clinically Important Pain Reduction Two Years Later

3S105 ACR Abstract: Osteoarthritis–Clinical (952–957)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].